Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-3.41% $1.980
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 252.42 mill |
EPS: | -0.330 |
P/E: | -6.00 |
Earnings Date: | Mar 21, 2024 |
SharesOutstanding: | 127.49 mill |
Avg Daily Volume: | 0.508 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.02x |
Company: PE -6.00 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.304 (-84.63%) $-1.676 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.818 - 2.14 ( +/- 8.18%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Boylan James P | Buy | 40 000 | Stock Option (Right to Buy) |
2024-02-09 | Gray Mary Ann | Buy | 40 000 | Stock Option (Right to Buy) |
2024-02-09 | Lindahl Richard S | Buy | 40 000 | Stock Option (Right to Buy) |
2024-02-09 | Gordon Carl L | Buy | 40 000 | Stock Option (Right to Buy) |
2024-02-09 | Chiniara Ellen | Buy | 40 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
94.03 |
Last 94 transactions |
Buy: 28 287 388 | Sell: 226 920 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.980 (-3.41% ) |
Volume | 0.141 mill |
Avg. Vol. | 0.508 mill |
% of Avg. Vol | 27.79 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 12 - 12:31 | buy | $1.795 | N/A | Active |
---|
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.